Key Stats for COMPASS Pathways Stock
- Price change for COMPASS Pathways stock: 42%
- $CMPS Share Price as of Apr. 20: $9
- 52-Week High: $10
- $CMPS Stock Price Target: $22
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
COMPASS Pathways (CMPS) stock jumped 42% on Monday and another 8% in pre-market on Tuesday after President Trump signed an executive order easing federal restrictions on psychedelic drugs, including psilocybin, MDMA, and LSD.
- The order calls for accelerating research and drug approvals for psychedelics to address the mental health crisis in America.
- The signing ceremony featured high-profile supporters, including Joe Rogan and Health Secretary Robert F. Kennedy Jr., which amplified media attention on the sector.
- COMPASS Pathways stock was the biggest single-stock winner of the day, outpacing peers like Atai Life Sciences and GH Research, which rose 33% and 30%, respectively.
The timing is particularly meaningful for COMPASS. The company is already the most advanced psychedelic drug developer in the world, with its lead drug COMP360, a synthetic psilocybin treatment for treatment-resistant depression, deep into Phase III clinical trials.
The first Phase III trial, COMP005, already hit its primary endpoint in June 2025. Enrollment for the second Phase III trial is now complete, and the company expects to file its NDA with the FDA, with data expected in early Q3 2026 being the final gating item.
CEO Kabir Nath has described the FDA relationship as positive and collaborative, with the agency encouraging an accelerated filing strategy including a rolling submission. That’s unusual for a psychiatry drug and signals genuine regulatory momentum.
The executive order adds a tailwind on top of that. Easier research restrictions could mean faster approvals and broader access once COMP360 reaches the market.
Roughly 3 million Americans live with treatment-resistant depression, a condition with few effective options today.
See analysts’ growth forecasts and price targets for COMPASS Pathways stock (It’s free) >>>
What the Market Is Telling Us About COMPASS Pathways Stock
COMPASS Pathways stock was already building momentum before today’s news.
The policy shift from Washington just poured fuel on the fire. That said, analysts are right to urge some caution.
Phase III data still needs to read out cleanly, the FDA process takes time, and commercialization requires building out clinical infrastructure.
But for investors looking at the psychedelic space, COMPASS stock stands apart from the rest.
It has the data, the regulatory relationships, and the head start. Today’s move reflects that.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does COMPASS Pathways Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
